Antiviral Activity of Narlaprevir Combined with Ritonavir and Pegylated Interferon in Chronic Hepatitis C Patients

J de Bruijne, Jilling Bergmann, HW Reesink, CJ Weegink, R Molenkamp, J Schinkel, XA Tong, J Li, MA Treitel, EA Hughes, JJ van Lier, AA van Vliet, HLA Janssen, Rob de Knegt

Research output: Contribution to journalArticleAcademicpeer-review

32 Citations (Scopus)


Narlaprevir (SCH 900518) is a potent inhibitor of the hepatitis C virus (HCV) nonstructural protein 3 serine protease that is primarily metabolized by the cytochrome P450-3A4 system. In order to explore the use of ritonavir-based pharmacokinetic enhancement of an HCV protease inhibitor, this study investigated the safety, tolerability, pharmacokinetics, and antiviral activity of narlaprevir (with or without ritonavir) administered as monotherapy and as combination therapy with pegylated interferon-alpha-2b (PEG-IFN-alpha-2b) to HCV genotype 1-infected patients. This was a randomized, placebo-controlled, two-period, blinded study in 40 HCV genotype 1-infected patients (naive and treatment-experienced). In period 1, narlaprevir was administered for 7 days as 800 mg three times daily without ritonavir or 400 mg twice daily with 200 mg ritonavir twice daily. In period 2, after a 4-week washout, the same dose and regimen of narlaprevir was administered in combination with PEG-IFN-alpha-2b for 14 days. Upon completion of period 2, all patients initiated PEG-IFN-alpha-26 and ribavirin treatment. A rapid and persistent decline in plasma HCV-RNA was observed in both treatment-experienced and treatment-naive patients during period 1, with a mean viral load decline of at least 4 log(10) in all treatment groups. A high percentage of both treatment-experienced (50%) and treatment-nave (>= 60%) patients had undetectable HCV-RNA (<25 IU/mL) after period 2. Standard of care resulted in sustained virological response (SVR) rates of 38% and 81% in treatment-experienced and treatment-nave patients, respectively. Narlaprevir (with or without ritonavir) alone or in combination with PEG-IFN-alpha-2b was safe and well tolerated. Conclusion: Narlaprevir administration resulted in a robust HCV-RNA decline and high SVR rates when followed by standard of care in both treatment-experienced and treatment-naive HCV genotype 1-infected patients. (HEPATOLOGY 2010;52:1590-1599)
Original languageUndefined/Unknown
Pages (from-to)1590-1599
Number of pages10
Issue number5
Publication statusPublished - 2010

Research programs

  • EMC MM-04-20-02-A

Cite this